FDA
-
-
-
-
-
-
-
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
-
-
-
-
-
-
-
Hillstream BioPharma (HILS) Prices 5.3M Share Offering at $0.50/sh
-
-
-
-
-
-
-
Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data
-
-
-
-
-
-
-
Hillstream BioPharma (HILS) Reports HSB-1216 and Pembrolizumab Demonstrated Significantly Greater Tumor Inhibition in Calu-1
-
-
-
-
-
-
-
Hillstream BioPharma (HILS) Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1
-
-
-
-
-
-
-
Hillstream BioPharma (HILS) Collaborates with Sapien Biosciences in Cancer Treatments
-
-
-
-
-
-
-
Hillstream BioPharma (HILS) Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

